ABSTRACTS

1. Snow A.D. and Altmann G.G. Relation of nucleolar size to DMH carcinogenesis and age in the columnar epithelial cells of the rat duodenum. Anatomical Record 205: 189, 1983. Poster presentation at the 96th session of the American Association of Anatomists, Atlanta, Georgia, April 1983.

2. Snow A.D. and Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. Laboratory Investigation 50: 55A, 1984 (Poster presentation at the 73rd International Academy of Pathology Meeting, San Francisco, California, March1984 and at Medical Research Day, University of Toronto, Toronto, Ontario, May 1984).

3. Snow A.D., Rae G., Giles A.R. and Kisilevsky R. Serum and tissue GAG changes during experimental amyloidosis. Do they play a role in factor X metabolism ? Thrombosis and Hemostasis 54: 33, 1985. Poster presentation at the 10th International Congress on Thrombosis and Hemostasis, San Diego, California, July 1985.

4. Snow A.D., Kisilevsky R. and Willmer J. Sulphated glycosaminoglycans, a common constituent of all amyloids: It's potential significance. Oral presentation at the 27th Annual National Student Research Forum, Galveston, Texas, April 1986.Winner of the Edwards S. Reynolds Award and the Mead Johnson Overall Excellence of Research Award.

5. Snow A.D. and Kisilevsky R. Plasma and splenic glycosaminoglycans during experimental amyloidosis and acute inflammation. Poster presentation at the 70th Annual Meeting of the American Association of Pathologists, St. Louis, Missouri, April 1986.

6. Willmer J.P., Snow A.D. and Kisilevsky R. The demonstration of sulphated glycosaminoglycans (GAGs) in association with the amyloidotic lesions of Alzheimer's disease. J Neuropath Exp Neur 45: 340, 1986. Poster presentation at the 62nd Annual Meeting of the American Association of Neuropathologists, Minneapolis, Minnesota, June 1986.

7. Kisilevsky R., Snow A.D. and Willmer J.P. Was Virchow right once more? Is amyloid truly carbohydrate? Poster presentation given at the Canadian Congress of Laboratory Medicine, Kingston, Ontario, Canada, June 1986.

8. Willmer J.P., Snow A.D. and Kisilevsky R. Sulphated glycosaminoglycans (GAGs) in association with neurofibrillary tangles and other filamentous

inclusions. Oral presentation given at the Xth International Congress of Neuropathology, Stockholm, Sweden, September 1986.

9. Kisilevsky R., Snow A.D., Subrahmanyan L., Boudreau L. and Tan R. What factors are necessary for the induction of AA amyloidosis? Oral presentation given at the International Course on Amyloidosis, Gronigen, The Netherlands, October 1986.

10. Snow A.D. and Kisilevsky R. An intimate ultrastructural association between sulphated proteoglycans and AA amyloid fibrils. Lab. Invest. 56:75A, 1987. Oral presentation given at the 76th International Academy of Pathology Meeting, Chicago, Illinois, March 1987.

11. Snow A.D., Willmer J., Kisilevsky R., DeArmond S. and Prusiner S. Sulfated glycosaminoglycans (GAGs) are present in the amyloid plaques of Alzheimer's, kuru, Creutzfeldt-Jakob, Gerstmann-Straussler and experimental scrapie. Fed Proc 46 (4), 1321, 1987 Poster presentation at the 71st meeting of the American Association of Pathologists, Washington, D.C., April, 1987.

12. Snow A.D., Kisilevsky R. and Wight T.N. Immunolocalization of heparan sulfate proteoglycans to AA amyloid deposition sites in spleen during experimental amyloidosis Oral presentation given at the Vth International Symposium on Amyloidosis, Hakone, Japan, October 1987.

13. Snow A.D., Mar H., Nochlin D. and Wight T.N. Corpora amylacea in aging and Alzheimer's brain contains antigenic sites for chondroitin sulfate and heparan sulfate proteoglycans. Oral presentation given at the Vth International Symposium on Amyloidosis, Hakone, Japan, October 1987.

14. Nochlin D., Sumi S.M., Bird T.D., Snow A.D., Masters C.L., and Beyreuther K. Familial dementia with unusual "senile" plaques with multiple amyloid cores positive for prion protein. Neurology 38 (3):266, 1988. Oral presentation given at the 40th Annual Meeting of the American Academy of Neurology, Cincinnati, Ohio, April 1988.

15. Snow A.D., Nochlin D., Lara S. and Wight T.N. Cationic dyes reveal proteoglycans to be structurally integrated within the amyloidotic lesions of Alzheimer's disease. Neurology 38 (3): 266, 1988. Oral presentation given at the 40th Annual Meeting of the American Academy of Neurology, Cincinnati, Ohio, April 1988.

16. Snow A.D., Lara S., Fingerle J., Certeza S., Wight T.N., R.P. Bolender and Clowes A.W. The effect of heparin on intimal extracellular matrix components after arterial injury. FASEB J 2: March, 1988. Oral presentation given at the 72nd Annual Meeting of the American Association of Pathologists, Las Vegas, Nevada, May 1988.

17. Snow A.D., Mar H., Nochlin D. and Wight T.N. Ultrastructural immunolocalization of heparan sulfate proteoglycans to amyloid fibrils in the neuritic plaques of Alzheimer's disease. J Neuropath Exp Neurol 47:355, 1988. Oral presentation given at the Meeting of the American Association of Neuropathologists, Charleston, South Carolina, June 1988.

18. Snow A.D., Mar H., Nochlin D. and Wight T.N. Congo red staining on 1 micron de-plasticized sections for detection of lesions in Alzheimer's disease and related disorders. Alzheimer disease and Associated Disorders 2:235, 1988. Poster presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, September 1988.

19. Snow A.D., Nochlin D., Sumi S.M., Bird T.D. and Wight T.N. Immunolocalization of heparan sulfate proteoglycans to "primitive plaques" and multi-core prion positive plaques in familial dementia. Alzheimer Disease and Associated Disorders 2:232, 1988. Poster presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, September 1988.

20. Snow A.D., Raskind M. and Wight T.N. The potential significance for the presence of glycosaminoglycans in the cerebrospinal fluid of normal aged and Alzheimer patients. Alzheimer disease and Associated Disorders 2:182, 1988. Oral presentation given at the First International Conference on Alzheimer's Disease and Related Disorders, Las Vegas, Nevada, September 1988.

21. Snow A.D., Mar H., Kisilevsky R., Hassell J.R. and Wight T.N. Ultrastructural immunolocalization of heparan sulfate proteoglycans to AA amyloid fibrils in spleen and liver during experimental amyloidosis. Poster presentation given at the Joint Meeting of the American Society for Cell Biology and the American Society for Biochemistry and Molecular Biology, San Francisco, CA, January 1989.

22. Wight T.N., Snow A.D., Bolender R.P., Lara S., Fingerle J., Certeza S. and Clowes A.W. Heparin influences the deposition of elastin, collagen and proteoglycans in the intimal extracellular matrix after arterial injury. Poster

presentation given at the Joint Meeting of the American Society for Cell Biology and the American Society for Biochemistry and Molecular Biology, San Francisco, CA, January 1989.

23. Snow A.D. and Wight T.N. Proteoglycans/ glycosaminoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 11:85-86, 1990. Oral presentation given at the American Health Assistance Foundation's 15th Anniversary Conference on Alzheimer's Disease Research, Tuscon, Arizona, February 1989.

24. Guiroy D.C., Snow A.D., Gajdusek D.C., Yanagihara R. and Garrutto R.M.Sulfated glycosaminoglycans in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam, Alzheimer's disease, Down's syndrome and Creutzfeldt-Jakob disease. UCLA Symposium, Molecular Biology of Aging, Santa Fe, New Mexico, March 1989.

25. Snow A.D., Nochlin D., DeArmond S.J., Prusiner S.B., Bird T.D., Sumi S.M. and Wight T.N. Identification and localization of heparan sulfate proteoglycans in PrP amyloid plaques in Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie.Alz Dis Assoc Dis 3:Suppl 1, 40, 1989. Oral presentation at the Second International Symposium on Familial Alzheimer's Disease, Seattle, WA, May 1989.

26. Snow A.D., Kinsella M.G., Prather P.B., Nochlin D., Podlisny M.B., Selkoe D.J., Kisilevsky R. and Wight T.N. A characteristic binding affinity between heparan sulfate proteoglycans and the A4 amyloid protein of Alzheimer's disease. J Neuropath Exp Neurol 48:352, 1989. Oral presentation at the American Association of Neuropathologists Meeting, Dallas, Texas, June 1989. Honorable mention for the Weil Award.

27. Snow A.D. The possible involvement of specific proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Oral presentation at the 13th International Symposium on Brain Sciences, La Jolla, CA, Feb. 1990.

28. Snow A.D., Mar H., Nochlin D., Sekiguchi R.T., Kimata K., Koike Y., and Wight T.N. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein containing lesions of Alzheimer's disease and Down's syndrome. Oral presentation at the 2nd International Conference on Alzheimer's Disease and Related Disorders, Toronto, Canada, July 1990.

29. Snow A.D., Mar H., Nochlin D., Sekiguchi R., Kimata R., Koike Y and Wight T.N. Heparan sulfate accumulation in the beta-amyloid protein containing

lesions of Alzheimer's disease and Down's syndrome is an early event. Poster presentation at the VIth International Symposium on Amyloidosis, Oslo, Norway, August 1990.

30. Snow A.D., Mar H., Nochlin D., Kresse H. and Wight T.N. Peripheral distribution of dermatan sulfate proteoglycans in amyloid-containing plaques and their presence in the neurofibrillary tangles of Alzheimer's disease. Poster presentation at the VIth International Symposium on Amyloidosis, Oslo, Norway, August 1990.

31. Snow A.D., Kinsella M.G., Sekiguchi R.T., Parks E. and Wight T.N. Binding by a high molecular weight heparan sulfate proteoglycan to the beta-amyloid protein of Alzheimer's disease. Oral presentation at the Western Connective Tissue Society Meeting, Ka-nee-ta, Oregon, May 1991.

32. Snow A.D., Kinsella M.G., Sekiguchi R.T., Nochlin D. and Wight T.N. Binding by a high molecular weight heparan sulfate proteoglycan to the extracellular domain of the beta-amyloid protein of Alzheimer's disease. Oral presentation at the 21st Annual Meeting Society For Neuroscience, New Orleans, Louisiana, November 1991.

33. Snow A.D. Specific proteoglycans in the pathogenesis of Alzheimer's disease. Oral presentation at the 14th Forum: Carbohydrates Coming of Age, Tokyo, Japan, May 1992.

34. Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. Brain amyloid accumulation in rats within 1 week of continuous infusion of beta-amyloid protein (1- 40) and an amyloid plaque co-component. Oral presentation at the 3rd International Conference on Alzheimer's Disease and Related Disorders, Padova, Italy, July 1992. Neurobiol Aging 13 (1), p. S101, 1992.

35. Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. A rat model to study the effects of BAP-containing amyloid in brain. Oral presentation at the 22nd Annual Meeting Society for Neuroscience, Anaheim, CA, October 1992. Soc. Neurosc. Abstracts, v. 18 (part 2), p.1465, 1992.

36. Snow A.D., Sekiguchi R.T., Nochlin D., Kimata K., Schreier W.A. and Morgan D.G. Deposition of congophilic and fibrillar ß/A4 amyloid in rat brain: A critical role of heparan sulfate proteoglycans. Poster presentation at the 82nd Annual Meeting of the United States and Canadian Academy of Pathology, New Orleans, March 1993. Lab Invest 68:121A, 1993.

37. Snow A.D., Sekiguchi R.T., Nochlin D., Schreier W.A. and Morgan D.G. An animal model to study the effects of fibrillar ß/A4 amyloid in brain. 1993 Pacific Northwest Alzheimer Disease Research Symposium, Vancouver, B.C., Canada, May 1993.

38. Snow A.D., Sekiguchi R.T., Nochlin D., Schreier W.A. and Morgan D.G. An animal model to study the effects of fibrillar ß/A4 amyloid in brain. Annual Meeting of the American Association of Neuropathologists, Salt Lake City, Utah, June 1993. J. Neuropath. Exp. Neurol. 52:286, 1993.

39. Snow A.D., Sekiguchi R.T., Potter-Perigo S., Braun K., Miller J., Ngo C. and Wight T.N. Increased expression of perlecan (heparan sulfate proteoglycan) and amyloid precursor protein during neuronal differentiation in murine embryonal carcinoma cells (P19). 23rd Annual Meeting Society for Neuroscience, Washington, D.C., November 1993. Soc. Neurosc. Abst. 19:623, 1993.

40. Fraser P.E., McLachlan D.R., Nguyen J.T., Mizzen C.A., Snow A.D., Surewicz W.T. and Kirschner D.A. Conformation and fibrillogenesis of Alzheimer Aß peptides with selected substitution of charged residues. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, MN, July 1994.

41. Snow A.D., Sekiguchi R.T., Miller J., Ngo C., Wight T.N. and Kinsella M.G. Differential affinity binding of vascular cell proteoglycans to the Aß of Alzheimer's disease. Poster presentation at the Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, MN, July 1994.

42. Snow A.D., Kinsella M.G., Sekiguchi R.T., and Wight T.N. Vascular cell derived proteoglycans bind with differential affinities to Aß of Alzheimer's disease. Poster presentation at the XII International Congress of Neuropathology, Toronto, Ontario, Canada, September 1994. Brain Pathology 4:545, 1994.

43. Snow A.D., Nochlin D., Miller J., Ngo C., Gordan M., Holcomb L., and Morgan, D.G. Infusion of Aß (1-40) plus perlecan into rat brain:further studies confirming a consistent animal model to study the consequences of fibrillar Aß persistence in vivo. Oral presentation at the 24th Annual Meeting of the Society for Neuroscience, Miami Beach, Florida, November 1994.

44. Snow A.D. Apolipoproteins and chaperons in Alzheimer's: promiscuous or innocent escorts? Oral presentation at the 28th Annual Winter Brain

Conference on Brain Research in Steamboat Springs, Colorado, January 1995.

45. Snow A.D., Nochlin D., Sekiguchi R., and Carlson S.S. Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Oral presentation at the Annual Meeting of the American Association of Neuropathologists, San Antonio, Texas, June 1995. J. Neuropath. Exp. Neurol. 54:436, 1995.

46. Snow A.D., Cummings J.A., Ngo C.T., Yang W., Nochlin D., Rimvall K., Sheardown M.J., and Judge M. Further studies implicating the importance of perlecan (a specific heparan sulfate proteoglycan) in an animal model of fibrillar Aß amyloid deposition in vivo: comparison of Aß (1-42) versus Aß (1-40). Oral Presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov. 1995. Soc. Neurosc. Abst. 21:1282, 1995.

47. Maresh G.A., Nochlin D., and Snow A.D. Perlecan mRNA levels in control and Alzheimer's disease brain using reverse transcription-polymerase chain reaction (RT-PCR). Poster presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA, November 1995. Soc. Neurosc. Abst. 21:205, 1995.

48. Castillo G.M., Miller J.D., Cummings J.A., Ngo C., Yang W., and Snow A.D. Purification and detailed characterization of perlecan isolated from the Engelbreth-Holm-Swarm (EHS) tumor for use in an animal model of Aß amyloid persistence in brain. Poster presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA November 1995. Soc. Neurosc. Abst. 21:673.15, 1995.

49. Fukuchi K., Ohman T., Snow A.D., LeBoeuf R.C., Furlong C.E., and Hassell, J.R. Effects of apolipoprotein E and perlecan on aggregation and toxicity of ß-amyloid protein expressed in cultured cells. Oral Presentation at the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 1995. Soc. Neurosc. Abst. 21:1282, 1995.

50. Snow A.D., Cummings J., Ngo C., Kimata K., Wight T.N., and Miller J.D.Localization of perlecan (or an immunologically related proteoglycan) to isolated microglia in vitro and to infiltrating microglia following infusion of beta-amyloid protein into rodent hippocampus. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

51. Castillo G.M. and Snow A.D. Perlecan binds to both beta-amyloid protein (Aß) 1-40 and 1-42, and is a potent accelerator and enhancer of Aß fibrillogenesis. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

52. Maresh G.A., Erezyilmaz D., Murry C.E., Nochlin D., and Snow A.D. Alterations in perlecan metabolism (decreased degradation) may be occurring in late stage Alzheimer's disease. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

53. Fukuchi K., Tokunaga T., Castillo G. M., Ngo C., Hassell J.R., and Snow A.D. Successful overexpression of the entire perlecan core protein (domains I-V) in COS cells for the ultimate development of perlecan transgenic mice. Presentation at the 5th International Conference on Alzheimer's Disease and Related Disorders, Osaka, Japan, July 1996.

54. Castillo G.M., Ngo C., and Snow A.D. Perlecan binding to Alzheimer's disease beta- amyloid protein (Aß) 1-40 regardless of the extent of fibrillogenesis. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C. Soc. Neurosc. Abst. 22:1172, 1996.

55. Miller J.D., Cummings J.A., Ngo C., Kimata K., Wight T.N., and Snow A.D. Immunolocalization of perlecan to microglia in vitro and in vivo. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., November 1996.

56. Snow A.D., Castillo G.M., Cummings J.A., Nochlin D., Yang W., Rimvall K., Sheardown M.J., and Judge M.E. A peptide to the perlecan binding domain of the beta-amyloid protein (Aß) is a potent inhibitor of Aß-perlecan binding and Aß fibrillogenesis in vitro and in vivo. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., November 1996.

57. Fukuchi K., Tokunaga T., Hassell J.R., and Snow A.D. Overexpression of perlecan and beta amyloid protein in transgenic mice. Presentation at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., November 1996.

58. Verchere C.B., D'Alessio D.A., Palmiter R.D., Baskin D.G., Snow A.D., Bonner-Weir S., and Kahn S.E. Characterization of islet amyloid in a transgenic mouse model of NIDDM. AFCR Regional Meeting, San Diego, CA, November 1996.

59. Snow A.D., Castillo G.M., Cummings J., Ngo C., and Maresh G. Further evidence implicating perlecan and other heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Oral presentation at the joint meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA, July 1997.

60. Snow A.D., Castillo G.M., Yang E., Ngo C., Hassell J.R., Tokunaga T., Hart M., and Fukuchi K. Overexpression of both perlecan and beta-amyloid precursor protein in P19 cells leads to a marked accumulation of beta-amyloid protein: new insights involving perlecan in Alzheimer's disease amyloidosis. XIII International Congress of Neuropathology, Perth, Australia, September 1997.

61. Castillo G.M., Lukito W., Ngo C., and Snow A.D. The glycosaminoglycans of perlecan bind beta-amyloid protein (Aß) and enhance Aß fibril formation in a sulfate content dependent manner. XIII International Congress of Neuropathology, Perth, Australia, September 1997.

62. Maresh G.A., Mueller C., Jin L.-W. and Snow A.D. Identification of a perlecan domain I (exon 5) splice variant specifically immunolocalized to the neurofibrillary tangles of Alzheimer's disease. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, October 25-30,1997.

63. Castillo G.M., Lukito W., Peskind E., Raskind M.and Snow A.D. Laminin is a potent inhibitor of Aß fibril formation and is an Aß-binding protein present in human blood and cerebrospinal fluid. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, October 25-30, 1997.

64. Lindsey D.P., Smith A., Hassell J.R., Snow A.D. and Fukuchi K. Transgenic mouse and cell culture models to study roles of perlecan (a specific heparan sulfate proteoglycan) in Alzheimer's disease. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans,
Louisiana, October 25-30, 1997.

65. Castillo G.M., Lukito W., Nochlin D., Ngo C. and Snow A.D. The glycosaminoglycans of perlecan bind beta-amyloid protein (Aß) and enhance Aß fibril formation in a sulfate content dependent manner. Presentation at the 27th Annual Meeting for Neuroscience, New Orleans, Louisiana, October 25-30, 1997.

66. Maresh G.A., Mueller C., Castillo G.M. and Snow A.D. Perlecan domain I splice variants in the pathogenesis of amyloid plaque and neurofibrillary tangle formation in Alzheimer's disease. Presentation at the 6th International

Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

67. McCurley D., Castillo G.M. and Snow A.D. Therapeutic implications of PTI-00703: A natural plant extract that is a potent dissolver of Alzheimer's disease amyloid. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18- 23, 1998.

68. Castillo G.M., Nochlin D., Wight T.N., Perry G., DeWitt D. and Snow A.D. Characterization of proteoglycans present in human Alzheimer's disease brain and in isolated amyloid plaque cores. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

69. Cummings J., Castillo G.M., Ngo C., Judge M.E., Sheardown M.J., Rimvall K. and Snow A.D. Artificial amyloid plaque core deposition into rodent hippocampus: A new animal model to study amyloid plaque persistence in vivo. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

70. Lukito W., Castillo G.M., Peskind E., Raskind M. and Snow A.D. Laminin and laminin fragments in human blood and cerebrospinal fluid bind Aß and maintain Aß solubility. Presentation at the 6th International Conference on Alzheimer's Disease and Related Disorders, Amsterdam, July 18-23, 1998.

71. Snow A.D., Mueller C., Castillo G.M. and Maresh G.A. Specific perlecan splice variants are immunolocalized to the amyloid plaques and neurofibrillary tangles of Alzheimer's disease. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

72. Snow A.D., Lukito W. and Castillo G.M. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

73. Snow A.D., Castillo G.M., Ngo C., Judge M.E., Sheardown M.J., Rimvall K. and Cummings J. A new animal model to study amyloid plaque persistence in vivo. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

74. Castillo G.M., Lukito W., Peskind E., Raskind R. and Snow A.D. Human blood and cerebrospinal fluid contain laminin fragments which bind Aß and

maintain Aß solubility. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7- 11, 1998.

75. Castillo G.M., Nochlin D., Wight T.N., Perry G., DeWitt D. and Snow A.D. Changes in distribution of specific classes of proteoglycans in human Alzheimer's disease brain. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7- 11, 1998.

76. Castillo G.M., Cummings J., Yang W., Judge M.E., Sheardown M.J., Rimvall K., Hansen J.B. and Snow A.D. The sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Presentation at the VIII International Symposium on Amyloidosis, Rochester, MN, August 7-11, 1998.

77. Verchere C.B., Andrikopoulos S., D'Alessio D.A., O'Brien K.D., Wight T.N., Snow A.D., Olin K.L., Chait A. and Kahn S.E. Role of apolipoprotein E and perlecan in islet amyloid formation in transgenic mice expressing human islet amyloid polypeptide. Presentation at the VIII International Symposium on Amyloidosis, Rochester, Minnesota, August 7-11, 1998.

78. Snow A.D., Castillo G.M., Cummings J.A., Vrablic A.S. and DeSantis D.A. NeurosharpTM: A new dietary supplement containing PTI-00703 for the prevention and treatment of brain amyloidosis associated with Alzheimer's disease and aging. Presentation at Experimental Biology '99, Washington, D.C., April 1999.

79. Snow A.D., Cummings J.A., Castillo G.M., Vrablic A.S. and DeSantis D.A. Further efficacy of PTI-00703: A dietary supplement which causes a dose-dependent inhibition of Alzheimer's disease amyloid deposition in a rodent model. Presentation at Experimental Biology '99, Washington, D.C., April 1999.

80. Snow A.D., Castillo G.M. and Cummings J.A. Perlecan and other heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Oral presentation at the 15th National Meeting of the British Neuroscience Association. Yorkshire, England, April 1999.

81. Snow A.D., Ngo C., Cummings J.A., Wight T.N., Lara S., Perry G., DeWitt D. and Castillo G.M. Perlecan and highly sulfated glycosaminoglycans induce spontaneous formation of Alzheimer's amyloid plaques *in vitro*. Oral presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, October 23-28, 1999.

82. Cummings J.A., Castillo G.M., Lukito W., Peskind E., Raskind M. and Snow A.D. Identification of a beta-amyloid protein binding site localized to the globular domain repeats on the laminin A chain. Oral presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, October 23-28, 1999.

83. Castillo G.M., J.A. Cummings and Snow A.D. Further efficacy of PTI-00703TM: A derivative from the amazon rain forest woody vine Uncaria tomentosa (cat's claw) that is a potent inhibitor of beta-amyloid protein fibrillogenesis. Oral presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, October 23-28, 1999.

84. Vrablic A.S., Castillo G.M., Cummings J.A., DeSantis D.A., Nochlin D. and Snow A.D. The combination of PTI-00703 and gingko biloba (NeurosharpTM) is an effective inhibitor of Aß amyloidosis associated with Alzheimer's disease and normal aging. Presentation at the 29th Annual Meeting Society for Neuroscience, Miami, Florida, October 23-28, 1999.

85. Snow A.D., Cummings J.A., Choi P.Y., Ngo C., Wight T.N., Perry G., DeWitt D., and Castillo G.M. Alzheimer's plaques re-created in a test tube: Further insights into the mechanism of amyloid plaque formation. Poster presentation at the World Alzheimer Congress 2000, Washington, D.C. July 9-13, 2000.

86. Cummings J.A., Castillo G.M., Choi P.Y., and Snow A.D. Disruption of pre-deposited Alzheimer's Aß 1-42 fibrils by PTI-00703 (Cat's claw derivative) in a rodent model of Aß fibrillogenesis. Poster presentation at the World Alzheimer Congress 2000, Washington, D.C. July 9-13, 2000.

87. Castillo G.M., Kirschner D.A., Yee A.G., and Snow A.D. Electron microscopy and x-ray diffraction studies further confirm the efficacy of PTI-00703TM (Cat's claw derivative) as a potent inhibitor of Alzheimer's beta-amyloid protein fibrillogenesis. Oral Presentation at the World Alzheimer Congress 2000, Washington, D.C. July 9-13, 2000.

88. Castillo G.M., and Snow A.D. The specific sulfated sugar (glucose pentasulfate) is a potent inhibitor of beta-amyloid protein fibrillogenesis. Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, November 4-9, 2000. Soc. Neurosc. Abstr. 26:299.4, 2000

89. Snow A.D., Choi P.Y., Cummings J.A., Wood S., Kirschner D.A., and Castillo G.M. Isolation and testing of the amyloid-inhibiting ingredients derived from the natural beta-amyloid protein fibrillogenesis inhibitor PTI-00703TM.

Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, November 4-9, 2000. Soc. Neurosc. Abst. 26:299.3, 2000.

90. Cummings J.A., Snow A.D., Castillo G.M., Choi P.Y., and van Kuppevelt T.H. Phage display generated heparan sulfate (HS) antibodies identify specific HS epitopes within the characteristic lesions of Alzheimer's disease. Presentation at the 30th Annual Meeting Society for Neuroscience, New Orleans, LO, November 4-9, 2000. Soc. Neurosc. Abst. 26:201.1, 2000.

91. Castillo G.M., Choi P.Y., Cummings J.A., and Snow A.D. Sulfated glycosaminoglycans and matrix molecules in the pathogenesis and treatment of amyloidosis in Alzheimer's disease. IXth International Symposium on Amyloidosis, Budapest, Hungary, July 2001. Amyloid: J. Protein Folding Disorders 8 (2) 188, 2001.

92. Snow A.D., Choi P.Y., Cummings J.A., Kirschner D.A., Yee A.G., Wood S., and Castillo G.M. Proteoglycans/glycosaminoglycans in the induction of Alzheimer's amyloid plaque formation and the discovery of natural anti-amyloid agents. IXth International Symposium on Amyloidosis, Budapest, Hungary, July 2001. Amyloid: J. Protein Folding Disorders 8 (2) 186, 2001.

93. Snow A.D., Rockenstein E., Cummings J.A., Castillo G.M., Choi P.Y., and Masliah E. PTI-777 treatment causes a potent reduction of amyloid plaque burden in a transgenic mouse model of Alzheimer's disease. Presentation at the 31st Annual Meeting Society for Neuroscience, San Diego, CA, November 10-15, 2001.

94. Castillo G.M., Choi P.Y., Cummings J.A., and Snow A.D. Inhibition of Parkinson's disease alpha-synuclein fibrillogenesis by PTI-777. Presentation at the 31st Annual Meeting Society for Neuroscience, San Diego, CA, November 10-15, 2001.

95. Cummings J.A., Kastin A.J., Pan W., Maresh G.A., Choi P.Y., Castillo G.M., and Snow A.D. Penetration of PTI-777 (amyloid inhibitory components of Uncaria tomentosa) across the blood-brain-barrier. Presentation at the 31st Annual Meeting Society for Neuroscience, San Diego, CA, November 10-15, 2001.

96. Snow A.D., Rockenstein E., Cummings J., Castillo G., Choi P., Nguyen B., Wood S., and Masliah, E. A potent reduction of amyloid plaque burden in a transgenic mouse model of Alzheimer's disease by the natural plant extract PTI-777. Presentation at the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 2002.

97. Castillo G., Kastin A, Pan W., Maresh G., Cummings J., Choi P., Nguyen B., Rockenstein E., Masliah E., and Snow A.D. Penetration of PTI-777 (amyloid inhibiting components of *Uncaria tomentosa*) across the blood-brain-barrier. Presentation at the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 2002.

98. Cummings J., Castillo G., Nguyen B., Choi P., Rockenstein E., Masliah E., Dennissen M., Jenniskens G., van Kuppevelt T., and Snow A.D. Heparan sulfate glycosaminoglycan accumulation in amyloid plaques and cerebrovascular amyloid deposits in APP transgenic mouse models. Presentation at the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 2002.

99. Choi P.Y., Nguyen B.P., Castillo G.M., Cummings J.A., Sanders V.J., and Snow A.D. Marked induction of Alzheimer's amyloid plaque formation *in vitro* by heparan sulfate glycosaminoglycans. Presentation at the 32nd Annual Meeting for Neuroscience, Orlando, FL, November 2002.

100. Nguyen B.P., Castillo G.M., Choi P.Y., Cummings J.A., and Snow A.D. Inhibition of Parkinson's disease alpha-synuclein/NAC fibrillogenesis by the natural plant extract PTI-777. Presentation at the 32nd Annual Meeting for Neuroscience, Orlando, FL, November 2002.

101. Snow A.D., Nguyen B.P., Choi P.Y., Cummings J.A., Sanders V.J., and Castillo G.M. Specific proteoglycans/ glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders. Oral presentation at the Sixth International Conference on Alzheimer's disease and Parkinson's disease, Seville, Spain, May 2003.

102. Snow A.D., Cummings J.A., Nguyen B.P., Lake T.P., Choi P.Y., Sanders V.J., Castillo G.M., Wood S., Rockenstein E., Masliah E. Amyloid plaque burden is markedly reduced in a transgenic mouse model of Alzheimer's disease by the natural plant extract PTI-777. Presentation at the 33nd Annual Meeting for Neuroscience, New Orleans, LO, November 2003.

103. Castillo G.M., Nguyen B.P., Lake T.P., Nomizu M., and Snow A.D. Screening and identification of laminin globular domain-derived peptides as disrupters of Aß fibrils. Presentation at the 33nd Annual Meeting for Neuroscience, New Orleans, LO, November 2003.

104. Nguyen B.P., Sanders V.J., Choi P.Y., Cummings J.A., Castillo G.M., and Snow A.D. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia.

Presentation at the 33nd Annual Meeting for Neuroscience, New Orleans, LO, November 2003.

105. Snow A.D., Sanders V.J., Choi P.Y., Cummings C.A., Castillo G.M., and Nguyen B.P. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia. Oral presentation at the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, April 2004.

106. Snow A.D., Cummings J.A., Nguyen B.P., Castillo G.M., Choi P.Y., Rockenstein E., and Masliah, E. Marked clearance of amyloid plaque burden and improved memory in a transgenic mouse model of Alzheimer's disease by PTI-0038 (A single component isolated from the natural plant extract PTI-777). Oral presentation at the Xth International Symposium on Amyloid and Amyloidosis, Tours, France, April 2004.

107. Snow A.D., Cummings J.A., Nguyen B.P., Castillo G.M., Choi P. Y., Rockenstein E., and Masliah E. PTI-0038 causes a marked clearance of amyloid plaque burden and improved memory in a transgenic mouse model of Alzheimer's disease. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

108. Cummings J.A., Nguyen B.P., Castillo G.M., Sanders V.J., Lake T.P., Choi P.Y., Rockenstein E., Masliah E., and Snow A.D. Potent reduction of microgliosis and astrocytosis in APP transgenic mice brain tissue by PTI-0038. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

109. Castillo G.M., Nguyen B.P., Lake T. P., Sanders V.J., Nomizu M., and Snow A.D. Identification of laminin globular domain-derived peptides as disrupters of Aß fibrils. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

110. Sanders V.J., Snow A.D., Choi P.Y., Cummings J. A., Castillo G.M., and Nguyen B.P. Alzheimer's amyloid plaque formation induced by sulfated glycosaminoglycans are resistant to degradation by proteases and microglia. Presentation at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 2004.

111. Snow A.D., Cummings J.A., Castillo G.M., Lake T.P., Choi P.Y., Sanders V.J., and Nguyen B.P. Development of Exebryl-1: A Disease Modifying Compound that Causes a Marked Clearance of Brain Amyloid Plaque Burden and Improved memory in Transgenic Mouse Models of Alzheimer's disease.

Presentation at "Alzheimer's Disease:From Molecular Mechanisms to Drug Discovery", Cancun, Mexico, December 11-17, 2004.

112. Snow A.D., Cummings J.A., Lake T.P., Masliah E., Rockenstein E., and Castillo G.M. Development of Novel Disease-Modifying Small Peptides that Cause a Reduction of Brain Amyoid Plaque Load and Improved Memory in a Transgenic Mouse Model of Alzheimer's Disease. Presentation at the 35th Annual Meeting of Neuroscience, Washington D.C., November 2005.

113. Cummings J.A., Masliah E., Rockenstein E., and Snow A.D. Heparan sulfate proteoglycan accumulation occurs concurrent with Aß amyloid plaque deposition in APP transgenic mouse models of Alzheimer's disease. Presentation at the 35th Annual Meeting of Neuroscience, Washington D.C., November 2005.

114. Snow A.D., Cummings J.A., and Lake T.P. Reduction of Brain Amyloid Load by the Small Molecule Therapeutic Exebryl-1 following Oral Treatment in a Transgenic Mouse Model of Alzheimer's Disease. Presentation at Neuroscience 2006, Atlanta, GA, November 2006.

115. Snow A.D., Cummings J.A., Lake T.P., Esposito L.A., Rockenstein E., Masliah E., Cheng F., Ferree A., Saha S., and Wolozin B. Proteoglycans/ glycosaminoglycans in the Pathogenesis of Alzheimer's and Parkinson's Disease and the Development of Novel Small Molcule Amyloid Disease-Modifying Therapeutics. Oral Presentation at the 8th International Conference on Alzheimer's and Parkinson's Disease, Saltburg, Austria, March 2007.

116. Esposito L.A., Cummings J.A., Lake T.P., Hudson F., Cheng F., Ferree A., Saha S., Wolozin B., and Snow A.D. Screening and identification of small molecule inhibitors of alpha-synuclein aggregation in A53T alpha-synuclein overexpressing cells treated with rotenone. Presentation at Neuroscience 2007, San Diego, CA, November 2007.

117. Snow A.D., Cummings J.A., Lake T.P., Hudson F.M., Esposito L.A., Kastin A., Hsuchou H, and Pan W. Blood-brain-barrier penetration of a novel disease-modifying small peptide (DP74) that reduced brain amyloid load and improves memory in a transgenic mouse model of Alzheimer's disease. Presentation at Neuroscience 2007, San Diego, CA, November 2007.

118. Snow A.D., Cummings J.A., Lake T.P., Esposito L.A., Hudson F.M., Hu H., Cam J.A., Aker J.R., and Runnels S. Exebryl-1: A novel small molecule drug that markedly reduces amyloid plaque load and improves memory, enters

human clinical trials. Presentation at International Conference on Alzheimer's Disease, Chicago, IL, July 2008.

119. Snow A.D., Cummings J.A., Lake T.P., Hudson F.M., Esposito L.A., Kastin A., Hsuchou H, and Pan W. Blood-brain-barrier penetration of a novel disease-modifying 7-mer peptide (DP-74) that reduces brain amyloid load and improves memory in a transgenic mouse model of Alzheimer's disease. Presentation at International Conference on Alzheimer's Disease, Chicago, IL, July 2008.

120. Snow A.D., Cummings J.A., Lake T.P., Hu Q., Esposito L.A., Cam J., Hudson M., Smith E., and Runnels S. Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. 9th International of Alzheimer's disease and Parkinson's disease, Prague, Czech Republic, March 2009.

121. Esposito L., Cummings J, Hudson M, Lake T., Hu Q., Cam J., Smith E., Rockenstein E., Masliah E., Wolozin B., and Snow A.D. Synuclere: Development of a novel small molecule that effectively reduces alpha-synuclein aggregation and improves motor dysfunction. 9th International of Alzheimer's disease and Parkinson's disease, Prague, Czech Republic, March 2009.

122. Snow A.D., Cummings J., Hudson M., Lake T., Hu Q., Cam J., Smith E., and Esposito L. Development of SynuclereTM: A novel small molecule that specifically targets alpha- synuclein aggregation and improves motor dysfunction. 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France, June 2009.

123. Snow A.D., Cummings J., Lake T., Hu Q., Esposito L., Cam J., Hudson M., Smith E., and Runnels S. Exebryl-1®: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. International Conference on Alzheimer's disease, Vienna, Austria, July 2009.

124. Snow A.D., Cummings J., Yadon M., Lake L., Hudson M., Jacobson E., Weigele M., Masliah E., Rockenstein E., Wolozin B., Kumar A., and Esposito E. Development of SynuclereTM: A novel disease-modifying drug for the reduction of brain alpha-synuclein aggregates in Parkinson's disease. BIT's 8th Annual Congress of 2010 International Drug Discovery Science and Technology, Beijing, China, October 2010.

125. Snow A.D., Cummings J., Yadon M., Lake T., Hudson M., Jacobson E., Hu Q., Cam J., Weigele M., Kumar A., Masliah E., Rockenstein E., Wolozin B., Runnels S., and Esposito L. Novel ways to reduce protein aggregation. 5th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs. San Diego, CA, February 2011.

126. Esposito L., Cummings J., Yadon M., Hudson M., Lake T., Hu Q., Cam J., Rockenstein E., Masliah E., and Snow A.D. SynuclereTM:A novel small molecule that effectively reduces alpha-synuclein aggregation and improves motor dysfunction as a potential parkinson's disease-modifying therapeutic. 10th International Conference on Alzheimer's and Parkinson's Diseases, Barcelona, Spain, March 2011.

127. Snow A.D., Lake T., Esposito L., Hanson K., Hu Q., Cam J., Yadon M., and Cummings J. Marked removal and clearance of AA amyloid deposits in target organs (kidney, liver and spleen) by the small molecule Systebryl™ following oral administration: A potential break-through drug for the treatment of systemic AA amyloidosis. The XIIIth International Symposium on Amyloidosis, Groningen, Netherlands, May 2012.

128. Cam J., Cummings J., Lake T., Hanson K., Esposito L., Yadon M., Snow A.D., and Hu Q. Identification of novel small molecules as tau protein aggregation inhibitors. Alzheimer's Association International Conference, Vancouver, British Columbia, Canada, July 2012.